AuD Pharma

AuD Pharma Spotlighting current research on ototoxic medications and pharmaceutical treatments for hearing loss.

“If your child is in a clinical trial for what could be a groundbreaking treatment to restore hearing, as a parent, you’...
14/05/2024

“If your child is in a clinical trial for what could be a groundbreaking treatment to restore hearing, as a parent, you’re going to notice the changes before a clinical investigator ever does. That’s what happened for patient 1, a baby with chubby arms and short, wispy blond hair, who was the first to receive Regeneron’s gene therapy for a type of genetic hearing loss in a phase 1/2 trial called CHORD.”

If your child is in a clinical trial for what could be a groundbreaking treatment to restore hearing, as a parent, you’re going to notice the changes before a clinical investigator ever does. | If your child is in a clinical trial for what could be a groundbreaking treatment to restore hearing, as...

12 Companies Revolutionizing Hearing Restoration and Hearing Loss Prevention
27/11/2023

12 Companies Revolutionizing Hearing Restoration and Hearing Loss Prevention

From new drug development, to stem cell and gene therapies. We take a deep dive look into the companies on the cutting edge of hearing loss treatment

https://investor.regeneron.com/news-releases/news-release-details/regeneron-shares-preliminary-results-showing-gene-ther...
27/10/2023

https://investor.regeneron.com/news-releases/news-release-details/regeneron-shares-preliminary-results-showing-gene-therapy?utm_campaign=db-oto+release&utm_source=linkedin&utm_medium=social

Global Phase 1/2 CHORD trial investigating otoferlin gene therapy (DB-OTO) represents Regeneron’s first auditory program and is currently enrolling patients DB-OTO is part of a growing pipeline of genetic medicines for hearing loss and other therapeutic areas that are being advanced by the company

“Sensorion submits clinical trial application for hearing loss study to United Kingdom’s Medicines and Healthcare produc...
13/07/2023

“Sensorion submits clinical trial application for hearing loss study to United Kingdom’s Medicines and Healthcare products Regulatory Agency.

The gene therapy for hearing loss treats otoferlin deficiency, an important protein for signal transduction in the ear.”

The gene therapy for hearing loss treats otoferlin deficiency, an important protein for signal transduction in the ear.

Decibel Therapeutics is conducting a Phase 1/2 CHORD clinical trial to evaluate their lead gene therapy candidate DB-OTO...
22/06/2023

Decibel Therapeutics is conducting a Phase 1/2 CHORD clinical trial to evaluate their lead gene therapy candidate DB-OTO in children with otoferlin-related hearing loss. Active clinical sites are recruiting in the US, UK and Spain. Learn more:

A Study of DB-OTO, an AAV Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations - Full Text View.

Address

3225 Eden Avenue
OH
45267

Telephone

+15135584611

Website

Alerts

Be the first to know and let us send you an email when AuD Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to AuD Pharma:

  • Want your practice to be the top-listed Clinic?

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram